Screener
Zevra Therapeutics, Inc. ZVRA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
FAQ
- What is Zevra Therapeutics, Inc.'s cash & equivalents?
- Zevra Therapeutics, Inc. (ZVRA) reported cash & equivalents of $145.32M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Zevra Therapeutics, Inc.'s cash & equivalents increased by 204.6% year-over-year, from $47.71M to $145.32M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s cash & equivalents has grown at a 71.4% compound annual growth rate (CAGR), from $4.21M to $62.41M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Zevra Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude